{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:32Z","timestamp":1794047492905,"version":"4.8.0"},"reference-count":16,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Inotuzumab ozogamicin (InO) is approved for treatment of relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL). Previous studies reported higher rates of post\u2013hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO than in those receiving chemotherapy prior to HSCT. It is unknown whether a lower InO dose would reduce the risk of post-HSCT SOS or affect efficacy. This study evaluated efficacy and safety of the currently approved InO starting dose and a lower dose in adults with R\/R ALL who were eligible for HSCT and were identified as being at higher risk of post-HSCT SOS. This open-label, phase IV study (NCT03677596) had two phases: in the run-in phase patients received InO at 1.2 mg\/m2\/cycle (N=22); in the randomized phase patients received InO starting at dose levels of 1.8 mg\/m2\/cycle (N=38) or 1.2 mg\/m2\/cycle (N=42). Primary endpoints were rate of SOS and rate of hematologic remission. Overall, SOS was reported in ten patients (9.8%) and in all cases was post-HSCT SOS. In patients who proceeded to HSCT, post-HSCT SOS rates were 20%, 28.6%, 25.8%, and 16.7% in 1.2 mg\/m2\/cycle (run-in), 1.2 mg\/m2\/cycle (randomized), 1.2 mg\/m2\/cycle (run-in and randomized), and 1.8 mg\/m2\/cycle (randomized) InO dosing subgroups, respectively. The rates of complete remission with or without complete hematologic recovery were 50.0%, 83.3%, 71.9%, and 68.4% in the respective subgroups. The study found that a starting dose of the 1.2 mg\/m2\/cycle demonstrated efficacy and safety consistent with those of the recommended 1.8 mg\/m2\/ cycle dose in adults with R\/R ALL who were eligible for HSCT and had a higher risk of post-HSCT SOS.<\/jats:p>","DOI":"10.3324\/haematol.2024.286091","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:25:08Z","timestamp":1738207508000},"page":"1736-1746","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study"],"prefix":"10.3324","volume":"110","author":[{"given":"Muhit","family":"\u00d6zcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Zarzycka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Demirkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"77263","doi-asserted-by":"crossref","unstructured":"Kantarijian H, Thomas D, O\u2019Brien S. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101(12):2788-2801.","DOI":"10.1002\/cncr.20668"},{"key":"77264","doi-asserted-by":"crossref","unstructured":"Rowe JM, Buck G, Burnett AK. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005; 106(12):3760-3767.","DOI":"10.1182\/blood-2005-04-1623"},{"key":"77265","doi-asserted-by":"crossref","unstructured":"Sive JI, Buck G, Fielding A. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol. 2012; 157(4):463-471.","DOI":"10.1111\/j.1365-2141.2012.09095.x"},{"key":"77266","unstructured":"US Food and Drug Administration. Besponsa prescribing information. 2017. Publisher Full Text|"},{"key":"77267","unstructured":"European Medicines Agency. Besponsa. 2017. Publisher Full Text|"},{"key":"77268","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Stock W, Stein AS. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv. 2017; 1(15):1167-1180.","DOI":"10.1182\/bloodadvances.2016001925"},{"key":"77269","doi-asserted-by":"crossref","unstructured":"Kantarijian H, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long\u2010term survival follow\u2010up from the randomized, phase 3 INO\u2010VATE study. Cancer. 2019; 125(14):2474-2487.","DOI":"10.1002\/cncr.32116"},{"key":"77270","doi-asserted-by":"crossref","unstructured":"Kantarijian H, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375(8):740-753.","DOI":"10.1056\/NEJMoa1509277"},{"key":"77271","doi-asserted-by":"crossref","unstructured":"Chen J, Haughey M, Vandendries E, DeAngelo DJ, Kantarjian HM, Ruiz-Garcia A. Characterization of the relationship of inotuzumab ozogamicin exposure with efficacy and safety end points in adults with relapsed or refractory acute lymphoblastic leukemia. Clin Transl Sci. 2021; 14(1):184-193.","DOI":"10.1111\/cts.12841"},{"key":"77272","doi-asserted-by":"crossref","unstructured":"Kebriaei P, Wilhelm K, Ravandi F. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013; 13(3):296-301.","DOI":"10.1016\/j.clml.2012.12.003"},{"key":"77273","doi-asserted-by":"crossref","unstructured":"Kantarijian H, Thomas D, Jorgensen J. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013; 119(15):2728-2736.","DOI":"10.1002\/cncr.28136"},{"key":"77274","doi-asserted-by":"crossref","unstructured":"Marks DI, Kebriaei P, Stelljes M. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019; 25(9):1720-1729.","DOI":"10.1016\/j.bbmt.2019.04.020"},{"key":"77275","doi-asserted-by":"crossref","unstructured":"Kayser S, Sartor C, Luskin MR. Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin. Haematologica. 2022; 107(9):2064-2071.","DOI":"10.3324\/haematol.2021.280433"},{"key":"77276","doi-asserted-by":"crossref","unstructured":"de Lima M, Kebriaei P, Lanza F. Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: a registry-based, observational study. Blood. 2022; 140(Supplement 1):6023-6025.","DOI":"10.1182\/blood-2022-160315"},{"key":"77277","doi-asserted-by":"crossref","unstructured":"Cassaday RD, Marks DI, DeAngelo DJ. Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020; 191(3):e77-e81.","DOI":"10.1111\/bjh.17029"},{"key":"77278","doi-asserted-by":"crossref","unstructured":"Mohty M, Malard F, Abecasis M. Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome\/ veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020; 55(3):485-495.","DOI":"10.1038\/s41409-019-0705-z"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11921\/78055","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11921\/78614","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11921\/78055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:05Z","timestamp":1794046085000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":16,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286091","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}